Columns

Looking forward to this year’s HDSA convention

I attended my first Huntington’s Disease Society of America (HDSA) Annual Convention when I was 9 years old, and have since gone more than 10 other times. Families, clinicians, healthcare professionals, pharmaceutical companies, and more are present at the three-day event, which changes location every year. The convention is…

Full Phase 3 trial data: Valbenazine eases chorea in Huntington’s

The oral therapy valbenazine significantly reduces involuntary muscle contractions, or chorea, and patient-reported disease burden in people with Huntington’s disease, according to results from the Phase 3 KINECT-HD clinical trial. Top-line data were announced by Neurocrine Biosciences, the therapy’s manufacturer, in 2021. The full findings have…

Huntington’s patients in US have new option of Austedo XR

Austedo XR, an extended-release oral formulation of Austedo (deutetrabenazine), is now commercially available in the U.S. as a treatment for adults with chorea, or uncontrolled muscle contractions, associated with Huntington’s disease. The new formulation is available in tablet strengths of 6 mg, 12 mg, and 24 mg,…

A gene-positive author shares stories of fellow HD heroes

A former columnist for Huntington’s Disease News, Erin Paterson, tested gene-positive for Huntington’s disease (HD) in 2006. She’s also the founder of Lemonade Press, a social enterprise focused on empowering people through storytelling. Through writing and speaking about genetic disease, depression, and infertility, she hopes to…